南京诺唯赞生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体请以南京诺唯赞生物 科技股份有限公司（以下简称"公司"）2025年年度报告中披露的财务数据为准，提请投资者注意投资风 险。 证券代码：688105证券简称：诺唯赞 公告编号：2026-005 一、2025年度主要财务数据和指标 单位：元 币种：人民币 2、影响经营业绩的主要因素 报告期内，公司生物制品类产品的增值税税率由3%调整至13%，对整体营收与盈利产生较大不利影 响。因未达成2023年限制性股票激励计划相关归属期业绩考核目标，公司于报告期末冲回对应归属期前 期已计提的股份支付费用。同时，公司基于谨慎性原则，冲回部分前期已确认的递延所得税资产，所得 税费用相应增加。 其他综合影响本报告期经营业绩的主要因素包括：公司积极拓展创新业务与海外市场，相关销售费用同 比增长；公司持续加强费用预算管理，不断提升研发与运营效率，剔除部分股份支付费用冲回影 ...

Core Viewpoint - The company reported its 2025 annual performance, showing a slight decline in revenue and net profit, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved operating revenue of 1.378 billion yuan, remaining stable compared to the same period last year [1] - The net profit attributable to the parent company was -16.97 million yuan, and the net profit after deducting non-recurring gains and losses was -79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Regulatory Impact - The value-added tax rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] Stock Incentive Plan - The company reversed previously accrued share-based payment expenses due to not meeting the performance assessment targets of the 2023 restricted stock incentive plan [1] - Additionally, the company, based on a principle of prudence, reversed part of the previously recognized deferred tax assets, leading to an increase in income tax expenses [1]

Core Viewpoint - The company reported its 2025 annual performance, showing stable revenue but a net loss, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved an operating revenue of 1.378 billion yuan, which is approximately flat compared to the same period last year [1] - The net profit attributable to the parent company was a loss of 16.97 million yuan, while the net profit after deducting non-recurring gains and losses was a loss of 79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Regulatory Impact - The value-added tax rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] Stock Incentive Plan - The company did not meet the performance assessment targets related to the 2023 restricted stock incentive plan, leading to a reversal of previously accrued share-based payment expenses at the end of the reporting period [1] Deferred Tax Assets - Based on a principle of prudence, the company reversed part of the previously recognized deferred tax assets, resulting in an increase in income tax expenses [1]

Core Viewpoint - The company reported its 2025 annual performance, showing stable revenue but a net loss, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved operating revenue of 1.378 billion yuan, which is approximately flat compared to the same period last year [1] - The net profit attributable to the parent company was a loss of 16.97 million yuan, while the net profit after deducting non-recurring gains and losses was a loss of 79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Financial Adjustments - The VAT rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] - Due to not meeting the performance assessment targets for the 2023 restricted stock incentive plan, the company reversed previously accrued share-based payment expenses at the end of the reporting period [1] - The company also reversed part of the previously recognized deferred tax assets based on a principle of prudence, leading to an increase in income tax expenses [1] Operational Factors - The company actively expanded its innovative business and overseas markets, resulting in a year-on-year increase in related sales expenses [1] - The company continued to strengthen budget management, improving research and operational efficiency, with a slight year-on-year decrease in research and management expenses after excluding the impact of reversed share-based payment expenses [1]

1.报告期内，预计实现的营业收入与上年同期基本持平，主要系公司生物制品类产品增值税率由3%调 整至13%，对整体营收与盈利产生不利影响。2.报告期内，公司积极应对外部环境变化影响，加强技术 与产品研发，优化降本增效举措，提升经营效率，不断巩固公司科技创新实力与市场竞争力。同时，公 司保持市场投入强度，积极拓展创新业务与海外市场，销售费用同比有所增长，对当期经营结果有一定 不利影响。3.报告期内，公司基于实际情况与审慎性原则，计提了部分信用减值损失和资产减值损失， 亦对当期经营结果产生一定不利影响。 格隆汇1月29日丨诺唯赞(688105.SH)公布，预计公司2025年度实现归属于母公司所有者的净利润-2,000 万元至-1,000万元。 实现归属于母公司所有者的扣除非经常性损益的净利润-8,500万元至-7,000万元。 2025年度，公司预计出现亏损，主要原因如下： （原标题：诺唯赞(688105.SH)：2025年度预亏1000万元至2000万元） ...

格隆汇1月29日丨诺唯赞(688105.SH)公布，预计公司2025年度实现归属于母公司所有者的净利润-2,000 万元至-1,000万元。 实现归属于母公司所有者的扣除非经常性损益的净利润-8,500万元至-7,000万元。 2025年度，公司预计出现亏损，主要原因如下： 1.报告期内，预计实现的营业收入与上年同期基本持平，主要系公司生物制品类产品增值税率由3%调 整至13%，对整体营收与盈利产生不利影响。2.报告期内，公司积极应对外部环境变化影响，加强技术 与产品研发，优化降本增效举措，提升经营效率，不断巩固公司科技创新实力与市场竞争力。同时，公 司保持市场投入强度，积极拓展创新业务与海外市场，销售费用同比有所增长，对当期经营结果有一定 不利影响。3.报告期内，公司基于实际情况与审慎性原则，计提了部分信用减值损失和资产减值损失， 亦对当期经营结果产生一定不利影响。 ...

南财智讯1月29日电，诺唯赞发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为-2000 万元至-1000万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为-8500万元 至-7000万元。2025年度，公司预计出现亏损，主要原因如下：报告期内，预计实现的营业收入与上年 同期基本持平，主要系公司生物制品类产品增值税率由3%调整至13%，对整体营收与盈利产生不利影 响；报告期内，公司积极应对外部环境变化影响，加强技术与产品研发，优化降本增效举措，提升经营 效率，不断巩固公司科技创新实力与市场竞争力。同时，公司保持市场投入强度，积极拓展创新业务与 海外市场，销售费用同比有所增长，对当期经营结果有一定不利影响；报告期内，公司基于实际情况与 审慎性原则，计提了部分信用减值损失和资产减值损失，亦对当期经营结果产生一定不利影响。 ...